Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
tiziana life sciences向所有10名非活性次進展性多發性硬化患者報告了爲期六個月的定性結果，這些患者參加了中等規模患者群體擴展接觸計劃。
- Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.
- FDA Allowance for an additional 20 Patients to be enrolled in the intranasal foralumab Multiple Sclerosis Expanded Access Program will allow further data collection and analysis.
- Applied for FDA Orphan Drug Designation of foralumab for na-SPMS
- 80%接受鼻內foralumab治療至少6個月的非活動性繼發性多發性硬化（na-SPMS）擴展使用患者 PET 成像顯示定性改善。
- FDA允許額外招募20名患者參加鼻內foralumab多發性硬化擴展使用計劃，以便進一步收集和分析數據。
- 申請FDA孤兒藥物foralumab治療na-SPMS的認定。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。